Susan M. Harrington

TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.

TL;DR: It is demonstrated that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy.

TL;DR: SABR induces an abscopal tumor-specific immune response in both the irradiated and nonirradiated tumors, which is potentiated by PD-1 blockade, and has the potential to translate into a potent immunotherapy strategy in the management of patients with metastatic cancer.

TL;DR: The tumor microenvironments of paired primary lung cancers and brain metastases are significantly different, such that many of the metastases lose PD-L1 expression, lymphocyte infiltration or both with greater discrepancies over time, limiting its use as a tissue-based predictive biomarker in lung cancer.

TL;DR: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival and may have important therapeutic implications for the management of mal cancers.